Vote Scores
Filings read through

Mirati Therapeutics, Inc.: how funds voted at the meeting of 13 Dec 2023

Meeting
Season
year to 30 June 2024
Filers reporting
350
Ballot items
4

350 filers on Form N-PX reported votes at the Mirati Therapeutics, Inc. meeting of 13 Dec 2023. The records fall into 4 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

This meeting is in the year to 30 June 2024. The latest season on file is the year to 30 June 2026. The page of Mirati Therapeutics, Inc. has the latest meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2024. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Advisory vote on executive pay (say-on-pay)

    7 vote records from 7 filers. 2 of the 7 filers that marked the item voted against management.

  2. Item 2: Advisory vote on pay tied to a merger or sale

    472 vote records from 335 filers. 229 of the 315 filers that marked the item voted against management. 20 filers gave no management mark.

    2 filers reported share counts too large for the holding. The share split leaves those figures out; the counts of filers keep them. The rule

    • Positions of 43 fund families
    • For 3
    • Against 40
    • Against management 39
  3. Item 3: EXTRAORDINARY TRANSACTIONS: management items

    The company's items in this category are shown together, because filers word and number them differently.

    171 vote records from 93 filers. 1 of the 93 filers that marked the item voted against management.

    • Positions of 35 fund families
    • For 34
    • Abstain or withhold 1
    • Against management 1
  4. Item 4: CORPORATE GOVERNANCE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    229 vote records from 111 filers. 14 of the 111 filers that marked the item voted against management.

    • Positions of 38 fund families
    • For 32
    • Against 5
    • Abstain or withhold 1
    • Against management 6

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Mirati Therapeutics, Inc., meeting of 13 Dec 2023Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Merger pay
AllianceBernsteinAgainst, against management
AllspringAgainst, against management
American CenturyAgainst, against management
BlackRock and iSharesAgainst, against management
BNY MellonAgainst, against management
Brighthouse FundsAgainst, against management
Charles SchwabAgainst, against management
Columbia ThreadneedleAgainst, against management
DimensionalAgainst, against management
DWSAgainst, against management
EquitableAgainst, against management
Federated HermesAgainst, against management
FidelityAgainst, against management
First TrustAgainst, against management
Franklin TempletonAgainst, against management
Goldman SachsAgainst, against management
Guggenheim and RydexAgainst, against management
InvescoAgainst, against management
J.P. MorganAgainst, against management
Jackson National fundsAgainst, against management
Janus HendersonAgainst, against management
John Hancock and ManulifeAgainst, against management
Lincoln FinancialAgainst
Macquarie and Delaware FundsAgainst, against management
Morgan Stanley, Eaton Vance and CalvertAgainst, against management
NationwideAgainst, against management
Natixis and Loomis SaylesAgainst, against management
Neuberger BermanAgainst, against management
Northern Trust and FlexSharesAgainst, against management
Nuveen and TIAAAgainst, against management
Pacific Life fundsAgainst, against management
PGIM and PrudentialAgainst, against management
PrincipalAgainst, against management
ProShares and ProFundsAgainst, against management
SEIAgainst, against management
State Street and SPDRFor
T. Rowe PriceAgainst, against management
TransamericaAgainst, against management
VanguardFor
Victory CapitalAgainst, against management
VirtusFor
VoyaAgainst, against management
WisdomTreeAgainst, against management

Questions

How many filers reported votes at the Mirati Therapeutics, Inc. meeting?
350 Form N-PX filers reported votes at the meeting of 13 Dec 2023. On say-on-pay, 2 of 7 filers that marked the item voted against management (28.6%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Mirati Therapeutics, Inc. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Mirati Therapeutics, Inc. with a meeting date within three days of 13 Dec 2023. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .